<DOC>
	<DOC>NCT00858234</DOC>
	<brief_summary>The clinical study determines recommended clinical dose, and evaluates the safety, tolerability, pharmacokinetics and efficacy of MK0683 in combination with bortezomib in patients with relapsed and/or refractory multiple myeloma in Japan.</brief_summary>
	<brief_title>Phase I Study of MK0683 in Combination With Bortezomib in Multiple Myeloma Patients (0683-098)</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patient Is 20 Years Of Age Or Older. Patient Has An Established Diagnosis Of Multiple Myeloma Based On The Myeloma Diagnostic Criteria Patient Has Received At Least 1 But Not More Than 3 Prior AntiMyeloma Regimens And Has Progressive Disease After The Most Recent Treatment Regimen Patient Must Have Adequate Organ Function Patient Has Had A Prior Allogeneic Bone Marrow Transplant Or Plans To Undergo Any Type Of Bone Marrow Transplantation During The Study Patient Has Known Hypersensitivity To Any Components Of Bortezomib Or MK0683 Patient Has Active Hepatitis B Or C, Plasma Cell Leukemia, Or Is Hiv Positive Patient Has Had Prior Treatment With MK0683 Or Hdac Inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>